This is a preview of subscription content, log in via an institution to check access.
Reference
Kuykendal AR, et al. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications. Annals of Oncology : 30 Dec 2012. Available from: URL: http://dx.doi.org/10.1093/annonc/mds618
Additional information
* National Comprehensive Cancer Network
Rights and permissions
About this article
Cite this article
Guideline-discordant ADT use in prostate cancer a costly concern. PharmacoEcon Outcomes News 670, 9 (2013). https://doi.org/10.1007/s40274-013-0106-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0106-2